Temporal aspects of improved survival with the implanted defibrillator (MADIT-II)

Moss, Arthur J.; Vyas, Anant K.; Greenberg, Henry; Case, Robert B.; Zaręba, Wojciech; Hall, William J.; Brown, Mary W.; McNitt, Scott; Andrews, Mark

doi:10.1016/j.amjcard.2004.04.025

Cited by 24 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety of this "watch and wait" approach would appear to be supported by both the survival curves in the SCD-HeFT and MADIT-II trials which did not separate until after 12 months post ICD insertion [18]. Our results have further support, as the benefit of ICD has been shown to be less pronounced in non-ischaemic cardiomyopathy patients and those with an LVEF between 31 and 34% [4].…”

Section: Discussionsupporting

confidence: 77%

Need and evolution of need for device therapy in a community heart failure population

Sulaiman

O’Loughlin

Daly

et al. 2008

European J of Heart Fail

View full text Add to dashboard Cite

Background: New guidelines for implantable cardiac defibrillators (ICD) and cardiac resynchronisation therapy (CRT) have expanded the potential use for device therapy. The implications of this on a community heart failure (HF) population are unknown. Aim: To assess the need for device therapy and the change in need over time. Methods: We reviewed device need in a community HF population using ESC guidelines. Change in need was assessed by comparing data between an annual visit called TP2 and an earlier visit called TP1. Patients' need and change in need between TP1 and TP2 was determined. Results: 210 patients were included; mean age 70 ± 12 years, 67% male and 54% ischaemic. At TP1, 34% of patients were suitable for ICD and 3% for CRT. At TP2, 22% and 1% were suitable respectively. Of those suitable for ICD at TP1, 19% lost the need at TP2; in addition 9% of patients unsuitable for ICD at TP1 had acquired the need by TP2. Fifty five percent of patients were unsuitable for ICD at either time point, and 16% were suitable at both time points. CRT need was negligible but also noted to change. Conclusion: ICD need is substantial in a community HF population, but CRT need is limited. ICD need changes significantly. Identifying those likely to change their need may optimise ICD use.

show abstract

Section: Discussionsupporting

confidence: 77%

Need and evolution of need for device therapy in a community heart failure population

Sulaiman

O’Loughlin

Daly

et al. 2008

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…On the contrary, this category of patients has been included in the prophylactic ICD studies. Interestingly, in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) and the Sudden Cardiac Death in Heart Failure (SCD-HeFT) trials it was observed that patients with QRS >150 or >120 ms, respectively had greater benefit from an ICD compared to patients with narrow QRS complex [24, 34]. Hence, this observation may support the indication of addition of an ICD in symptomatic patients with wide QRS complex who are planned for a CRT implantation.Conversely, it can be argued that implantation of CRT could be sufficient in these patients as the CARE-HF study showed a significant reduction in sudden cardiac death as well.…”

Section: Discussionmentioning

confidence: 55%

Impact of Implantable Defibrillators and Resynchronization Therapy on Outcome in Patients with Left Ventricular Dysfunction – A Meta-Analysis

Abdulla

Haarbo²,

Køber³

et al. 2006

Cardiology

View full text Add to dashboard Cite

Background: The clinical benefits of cardiac resynchronization therapy (CRT) and primary prophylactic implantable cardioverter defibrillator (ICD) in patients with left ventricular systolic dysfunction (LVSD) are debated. Objective: To evaluate by a meta-analysis the effect of CRT and prophylactic ICD therapy in patients with LVSD. Methods: Eligible trials evaluating the effect of CRT vs. no-CRT, ICD vs. no-ICD and adding ICD to CRT vs. no-ICD were selected and meta-analyzed. The outcomes were: all cause mortality, cardiac mortality, hospitalization for heart failure and change in exercise tolerance and New York Heart Association class. Results: Implantation of CRT reduced all cause mortality odds ratio (OR) = 0.73 (0.60–0.89) p = 0.002 and hospitalization for heart failure OR = 0.60 (0.45, 0.80) p = 0.001, increased peak oxygen consumption by 1.77 (0.32–3.22) ml/kg/min p = 0.017 and improved New York Heart Association class by at least one class with OR = 1.52 (1.30, 1.77) p < 0.0001. Implantation of ICD reduced all-cause mortality OR = 0.75 (0.59–0.96) p = 0.025 and cardiac mortality OR = 0.63 (0.48, 0.82) p = 0.001. Adding ICD to CRT reduced all cause mortality OR = 0.69 (0.53–0.91) p = 0.008. Conclusion: Selective patients with LVSD benefit from CRT, ICD or both. Further investigations are necessary to clarify which patients benefit most from a single or combined device implantation.

show abstract

“…In the Multicenter Automatic Defibrillator Implantation Trial -II, implantation of an AICD more than 30 days postinfarction was associated with a significant reduction in sudden cardiac death and total mortality [61]. There was no apparent benefit of AICD implantation on total mortality for the first year postimplantation.…”

Section: The Role Of Aldosterone and Activation Of Mineralocorticoid mentioning

confidence: 90%

Role of Aldosterone Blockade in Heart Failure

Pitt

2005

Heart Failure Clinics

View full text Add to dashboard Cite

Temporal aspects of improved survival with the implanted defibrillator (MADIT-II)

Cited by 24 publications

References 8 publications

Need and evolution of need for device therapy in a community heart failure population

Need and evolution of need for device therapy in a community heart failure population

Impact of Implantable Defibrillators and Resynchronization Therapy on Outcome in Patients with Left Ventricular Dysfunction – A Meta-Analysis

Role of Aldosterone Blockade in Heart Failure

Contact Info

Product

Resources

About